Q2 FY2026 EarningsQ2 FY26 results significantly outperformed consensus expectations across all major metrics: revenue reached $163.5M vs. $131.2M expected, and GAAP EPS was -$0.01 vs. -$0.08 expected. The top-line beat was primarily driven by a surge in IP and Other revenue following an amended license agreement with Nicoya, while operating loss narrowed substantially to -$7.0M compared to the anticipated -$55.6M. Full-year FY26 revenue guidance of $560M-$585M remains strong, supported by pipeline progress in ModeX and GLP-1/Glucagon dual agonists.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Opko Health(OPK) the Revenue is 163.5 M (+4.27%), Beat estimate;the EBIT is -7 M (+88.33%), Beat estimate;the EPS is -0.01 (+94.74%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.16B4.27%
0.13B16.31%
+0.03B20.58%
EBITExceed expectations
-0.01B88.33%
-0.06B7.32%
+0.05B81.01%
EPSExceed expectations
-0.0194.74%
-0.080457.69%
+0.070437.05%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf